DiaMonTech AG

  • WKN: A255G4
  • ISIN: DE000A255G44
  • Land: Deutschland

Nachricht vom 16.09.2019 | 09:00

DiaMonTech: Innovative, pain-free blood glucose monitoring to improve the quality of life of diabetes patients in Germany with the help of local pharmacies

DGAP-News: DiaMonTech GmbH / Key word(s): Alliance

16.09.2019 / 09:00
The issuer is solely responsible for the content of this announcement.


DiaMonTech: Innovative, pain-free blood glucose monitoring to improve the quality of life of diabetes patients in Germany with the help of local pharmacies

Berlin, 16 September 2019 - Germany's pharmacists want to ease life for millions of diabetics by offering them pain-free blood glucose monitoring without taking blood as soon as possible. The Deutscher Apothekerverband e. V. (DAV; German Association of Pharmacists) and DiaMonTech GmbH, a young and innovative medical technology company, intend a strategic cooperation to significantly improve the care of diabetes patients and to take an innovative step into the future.

"The Deutscher Apothekerverband is an important partner for us as the umbrella organization with more than 19,000 pharmacies in Germany. The signing of the Letter of Intent confirms the mutual will to cooperate in a trusting and productive manner. Diabetes patients need personal care and access to the latest technology. They should be able to get both from the local pharmacy." says Thorsten Lubinski, co-founder and CEO of DiaMonTech GmbH.

The DAV and DiaMonTech are initially striving to carry out practical tests of the already CE-certified "DMT Base" in selected pharmacies. The "DMT Base" is currently optimized for use in professional environments (e.g. diabetes centers). The patient places his finger on a sensor field for a few seconds and the blood sugar is shown categorized on a display. The blood sugar level can be measured precisely and painlessly without a drop of blood. DiaMonTech thus offers a solution for diabetes patients worldwide that offers them the opportunity to significantly improve their quality of life.

The smaller "DMT Pocket" is currently in development with market launch expected by the end of 2020. This device is supposed to have the size of a smartphone and could therefore become a constant accompaniment for diabetes patients. In Germany alone, around 7.2 million people are currently affected.

About DiaMonTech
DiaMonTech GmbH is a medical technology company that specializes in the development, design and sale of products for medical diagnostics. The patented photothermal diagnostic technology based on infrared lasers enables the precise measurement of relevant blood parameters. The first application is the non-invasive blood glucose measurement, which enables an accurate and fast measurement without pain.

More information about DiaMonTech can be found at www.diamontech.de.

Press contact
Alexander Neblung
Kirchhoff Consult AG
Phone +49 40 60 91 86 70
E-mail diamontech@kirchhoff.de



16.09.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


show this

GBC-Fokusbox

International School Augsburg (ISA): Investment in den Rohstoff Bildung

Die in Gersthofen bei Augsburg ansässige International School Augsburg (ISA) plant als erste internationale Schule in Deutschland den Gang an die Börse und macht damit erstmals das Thema „Bildung“ unter ESG-Kriterien investierbar. Die ISA, an der derzeit rund 330 Schüler eingeschrieben sind, ist als internationale Schule Teil eines globalen Schulnetzwerkes, welches das in Deutschland anerkannte IB-Diploma als Hochschulzugangsberechtigung anbietet. Im Rahmen des geplanten Campus-Neubaus sollen die Kapazitäten erweitert und damit die hohe Nachfrage nach privaten Bildungsleistungen in Deutschland und in der Region erfüllt werden. GBC-Analyst Cosmin Filker hat mit dem ISA-Vorstand Marcus Wagner gesprochen.

Aktueller Webcast

Stealth BioTherapeutics

H.C. Wainwright Global Life Sciences Conference at 7:00 am ET

09. März 2021

Aktuelle Research-Studie

Media and Games Invest plc

Original-Research: Media and Games Invest plc (von First Berlin Equity Research GmbH): Buy

05. März 2021